Lesson
Start with Site, Stage, and Intent
Gynecologic oncology is not one disease. The primary tissue, histology, grade, anatomic spread, operability, and therapeutic intent determine whether surgery, radiation, systemic treatment, maintenance, surveillance, or palliation belongs first.
- Primary site
- Histology
- Stage
- Cytoreduction
- Treatment intent
- Sequence
Ovary, tube, peritoneum, endometrium, cervix, vulva, or vagina
Define the tumor rather than the organ alone
Show where disease is and what local treatment can accomplish
Curative, adjuvant, neoadjuvant, maintenance, control, or palliation
Localize the primary disease
Ovarian, fallopian tube, primary peritoneal, endometrial, cervical, vulvar, and vaginal cancers arise from different tissues. Preserve the primary site even when advanced disease fills the pelvis or peritoneum.
Name histology and grade
High-grade serous, low-grade serous, endometrioid, clear cell, mucinous, carcinosarcoma, squamous, adenocarcinoma, germ cell, stromal, and sarcoma biology cannot be exchanged. Pathology review can change the entire drug set.
Stage before choosing intensity
Surgical and imaging information define local, regional, nodal, peritoneal, and distant spread. Stage combines with residual disease and molecular risk rather than functioning as a complete treatment plan by itself.
Assign surgery its correct role
Surgery can diagnose, stage, cure localized disease, preserve fertility in selected patients, reduce macroscopic burden, or relieve symptoms. Operability and likelihood of meaningful cytoreduction determine sequence.
State treatment intent
Curative local therapy, adjuvant risk reduction, neoadjuvant downstaging, maintenance, recurrent-disease control, and palliation have different endpoints. An active drug can still be wrong when used in the wrong state.
Quick check
Lesson
Turn Molecular Results into Validated Decisions
Precision oncology requires more than a positive marker. Each assay must connect to a cancer type, specimen, threshold, line of therapy, regulatory indication, hereditary implication, and patient-specific safety plan.
- BRCA
- HRD
- MMR and MSI
- POLE and p53
- HER2 and PD-L1
- FRalpha and KRAS
Match platinum response and PARP indication
Connect assay to checkpoint evidence and hereditary risk
Refine endometrial prognosis and targeted therapy
Use companion testing in the correct ovarian histology
Separate germline from tumor testing
A pathogenic germline BRCA or Lynch-associated result can change treatment and family counseling. A somatic result can change tumor therapy without proving an inherited syndrome. Variants of uncertain significance are not actionable pathogenic variants.
Read repair biomarkers precisely
BRCA loss and HRD can identify selected ovarian maintenance strategies. MMR deficiency and MSI-H predict immune responsiveness and can signal Lynch syndrome. The assay, disease, and product indication must align.
Use endometrial molecular class
POLE-ultramutated, MMR-deficient, no-specific-molecular-profile, and p53-abnormal groups refine prognosis and adjuvant decisions when integrated with histology, stage, grade, invasion, and lymphovascular involvement.
Match target to the product
HER2 in uterine serous carcinoma, PD-L1 in selected cervical therapy, FRalpha in platinum-resistant ovarian disease, and KRAS in recurrent low-grade serous ovarian cancer each use disease-specific evidence and testing.
Respect companion diagnostics
Confirm whether an FDA-authorized companion diagnostic, assay platform, positivity threshold, and specimen are required. A target result from a nonvalidated context does not automatically establish eligibility.
Quick check
Lesson
Design Primary Ovarian Cancer Therapy
Epithelial ovarian, fallopian tube, and primary peritoneal cancers often share a treatment architecture: expert cytoreduction when feasible, platinum-taxane chemotherapy, biomarker testing, and selected anti-VEGF therapy.
- Mullerian continuum
- Resectability
- Cytoreduction
- Carboplatin
- Paclitaxel
- Bevacizumab
Choose primary surgery or neoadjuvant therapy
Aim for safe maximal removal of macroscopic disease
Design renal exposure, premedication, marrow, and nerve monitoring
Move from primary therapy into a matched maintenance decision
Preserve histologic diversity
High-grade serous disease is common and often arises from the tubal fimbria, but not every ovarian mass is epithelial high-grade serous cancer. Germ cell, stromal, borderline, low-grade serous, mucinous, clear cell, and endometrioid tumors need distinct evaluation.
Choose the surgical sequence
Primary cytoreductive surgery is favored when complete gross resection appears safely achievable. Neoadjuvant platinum-taxane therapy followed by interval surgery can fit unresectable distribution or high operative risk after tissue confirmation.
Use the systemic backbone
Carboplatin plus paclitaxel remains a core first-line backbone. Carboplatin uses Calvert exposure design, while paclitaxel requires protocol dosing, hypersensitivity premedication, marrow monitoring, neuropathy assessment, and liver review.
Place bevacizumab selectively
Bevacizumab can be combined with chemotherapy and continued in maintenance in selected advanced disease. Recent surgery, wound healing, bowel involvement, fistula or perforation risk, blood pressure, urine protein, thrombosis, and bleeding must be reviewed.
Measure response and prepare maintenance
Track symptoms, examination, imaging, treatment tolerance, and CA-125 when informative. Obtain germline and tumor testing early enough that a response can transition into an evidence-matched maintenance choice.
Quick check
Lesson
Select Ovarian Maintenance and Recurrent Therapy
Maintenance is not automatic and recurrence is not one state. Platinum response, recurrence interval, BRCA or HRD, FRalpha, KRAS, prior PARP or bevacizumab, residual toxicity, symptoms, and goals define the next treatment.
- Platinum response
- BRCA and HRD
- PARP inhibitor
- FRalpha ADC
- KRAS LGSOC
- Clinical trial
Use a product-specific PARP indication
Read interval, prior benefit, and residual toxicity together
Confirm companion test and protect the ocular surface
Use the accelerated co-pack only in its defined histology
Use first-line maintenance precisely
Current product-specific PARP indications depend on response to platinum and biomarker-defined populations. Olaparib, olaparib plus bevacizumab, and niraparib pathways cannot be treated as interchangeable all-comer choices.
Monitor PARP therapy longitudinally
Obtain baseline and serial blood counts, review organ function and interactions, and investigate persistent cytopenias. Fatigue and gastrointestinal effects are common; MDS or AML is rare but serious. Niraparib adds product-specific blood pressure and heart-rate concerns.
Classify recurrent disease
A meaningful platinum-free interval can support platinum retreatment, but prior response, cumulative toxicity, resectability, and current biology matter. Early progression shifts toward nonplatinum, targeted, trial, and symptom-directed strategies.
Use FRalpha-directed therapy correctly
Mirvetuximab soravtansine is for FRalpha-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior regimens. Companion testing and a complete ocular prevention and monitoring protocol are mandatory.
Recognize low-grade serous biology
Avutometinib plus defactinib has accelerated approval for KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy. Confirm histology, mutation, dosing calendar, ocular, skin, muscle, liver, cardiac, and interaction monitoring.
Quick check
Lesson
Integrate Localized Endometrial Risk
Most endometrial cancers are diagnosed at a potentially curable stage. Surgery establishes the pathologic and molecular risk needed to decide whether observation, vaginal brachytherapy, pelvic radiation, chemotherapy, or combined therapy adds value.
- Tissue diagnosis
- Surgery
- Molecular class
- Adjuvant radiation
- Adjuvant chemotherapy
- Fertility preservation
Diagnosis begins with endometrial tissue
Define invasion, spread, and residual risk
Integrate POLE, MMR, p53, and pathology
Match observation, radiation, or chemotherapy to relapse pattern
Require tissue diagnosis
Abnormal bleeding can trigger imaging, but definitive diagnosis requires endometrial tissue. Histology, grade, and molecular testing begin the risk assessment before surgery and are refined after staging.
Use standard surgical architecture
Total hysterectomy with bilateral salpingo-oophorectomy and appropriate nodal assessment is standard for most operable disease. Surgical approach and staging are individualized by histology, spread, comorbidity, and expertise.
Combine molecular and pathologic risk
POLE, MMR, p53, and no-specific-molecular-profile classification works with histology, stage, grade, myometrial invasion, lymphovascular invasion, cervical involvement, and nodes. No single element replaces the others.
Target the expected recurrence route
Observation, vaginal brachytherapy, pelvic radiation, chemotherapy, or combined treatment should address the predicted local and distant relapse risk. More therapy is not automatically better when absolute benefit is small.
Treat fertility sparing as a protocol
Selected grade 1 endometrioid cancer confined to the endometrium can use progestin-based fertility-sparing therapy after expert review. Serial tissue response, adherence, hereditary assessment, and definitive-surgery planning are essential.
Quick check
Lesson
Match Advanced Endometrial Therapy to Biology
Primary advanced and recurrent endometrial cancer now uses chemotherapy, immunotherapy, endocrine therapy, HER2-directed treatment, surgery, radiation, or trials according to molecular subtype, histology, disease tempo, and prior treatment.
- Carboplatin and paclitaxel
- Pembrolizumab
- Dostarlimab
- Durvalumab
- Hormone therapy
- HER2
Build the first-line cytotoxic platform
Match pembrolizumab, dostarlimab, or dMMR durvalumab
Use endocrine pressure in selected indolent disease
Add trastuzumab with disease-specific testing and cardiac monitoring
Use chemoimmunotherapy by label
Pembrolizumab or dostarlimab can combine with carboplatin and paclitaxel followed by maintenance in adults with primary advanced or recurrent endometrial cancer. Durvalumab with chemotherapy followed by durvalumab is restricted to dMMR disease.
Separate products and protocols
Checkpoint inhibitors share immune biology but not identical populations, schedules, evidence, or labeling. Review autoimmune disease, transplant, organ function, steroids, reproductive risk, and baseline endocrine status before treatment.
Use dMMR and MSI-H intentionally
MMR deficiency or MSI-H predicts strong immune sensitivity and can qualify selected later-line monotherapy. The tumor result can also signal Lynch syndrome and should trigger hereditary evaluation when appropriate.
Preserve endocrine options
Low-grade, indolent, hormone receptor-positive endometrioid disease can use progestins, aromatase inhibition, or other endocrine strategies when disease tempo and burden allow. Rapid symptomatic disease usually needs faster control.
Recognize HER2-positive serous disease
HER2-positive uterine serous carcinoma can receive trastuzumab with carboplatin and paclitaxel in appropriate settings. Use disease-specific HER2 interpretation and baseline plus serial cardiac assessment.
Quick check
Lesson
Connect HPV Prevention to Curative Cervical Therapy
Cervical cancer care spans HPV vaccination and screening, diagnostic staging, fertility-aware early surgery, and definitive chemoradiation. These layers are connected but are not interchangeable.
- HPV
- Screening
- Early surgery
- External beam radiation
- Brachytherapy
- Cisplatin and pembrolizumab
Reduce oncogenic infection before invasive disease
Move abnormal tests into tissue and stage
Use fertility-aware or definitive surgery
Complete external beam, brachytherapy, cisplatin, and selected pembrolizumab
Keep prevention distinct
Persistent high-risk HPV drives most cervical cancers. Vaccination prevents many infections, and screening reduces incidence and mortality, but neither treats established invasive disease.
Stage before local therapy
Tumor size, stromal invasion, parametria, vagina, bladder or rectum, lymph nodes, distant disease, histology, pregnancy, and fertility goals guide surgery or radiation.
Select early local treatment
Conization, trachelectomy, simple hysterectomy, radical hysterectomy, nodal assessment, or radiation can fit selected early disease. Minimally invasive radical hysterectomy is not assumed equivalent to open surgery in eligible patients.
Protect the chemoradiation backbone
Locally advanced disease uses external-beam radiation, brachytherapy, and concurrent weekly cisplatin. Monitor kidney function, hydration, magnesium, marrow, hearing, neuropathy, and the total radiation timeline.
Place pembrolizumab by stage
Pembrolizumab is FDA approved with chemoradiotherapy for FIGO 2014 stage III to IVA cervical cancer, followed by maintenance under the approved schedule. Do not extend the approval to every early stage.
Quick check
Lesson
Re-stage Recurrent and Metastatic Cervical Cancer
Recurrent cervical cancer ranges from selected locally salvageable disease to widespread metastatic disease. Prior radiation, recurrence location, PD-L1, symptoms, tissue-healing risk, prior therapy, and goals determine local or systemic treatment.
- Re-staging
- PD-L1
- Platinum and taxane
- Pembrolizumab
- Bevacizumab
- Tisotumab vedotin
Find selected isolated disease still open to curative treatment
Add pembrolizumab to the appropriate chemotherapy backbone
Interrogate fistula, bleeding, wound, bowel, renal, and vascular risk
Make ocular prophylaxis and monitoring part of every infusion
Re-stage before assuming intent
Review recurrence site, volume, prior surgical margins, radiation fields, nodes, distant metastases, performance status, symptoms, and organ function. Selected central or oligometastatic recurrence can have a local salvage pathway.
Use first-line systemic therapy precisely
Persistent, recurrent, or metastatic PD-L1-positive disease can use pembrolizumab with platinum-taxane chemotherapy, with bevacizumab added when appropriate. Confirm the validated PD-L1 assay and current protocol.
Interrogate bevacizumab risk
Prior pelvic radiation, active bleeding, fistula, bowel or bladder involvement, recent surgery, uncontrolled hypertension, proteinuria, thrombosis, and wound healing can change whether bevacizumab is usable.
Use tisotumab vedotin after chemotherapy
Tisotumab vedotin has traditional approval for recurrent or metastatic disease progressing on or after chemotherapy. Tissue factor targeting delivers a microtubule-disrupting payload.
Make ocular prophylaxis part of the ADC dose
Tisotumab requires baseline and serial eye care, prescribed topical ocular medicines, cooling during infusion, contact-lens restrictions, and prompt management of visual symptoms. Bleeding, neuropathy, and pulmonary toxicity also require monitoring.
Quick check
Lesson
Treat Toxicity and Supportive Care as Core Oncology
The same regimen can injure marrow, nerves, kidneys, vessels, bowel, eye, endocrine organs, fertility, and quality of life through different mechanisms. Safe care attributes toxicity, calculates exposure, and supports the person before crisis.
- Calvert formula
- Myelosuppression
- Neuropathy
- Immune toxicity
- ADC ocular care
- Supportive and reproductive care
Link target exposure to renal clearance
Identify the component and cumulative pattern
Use organ-specific early recognition and protocol care
Integrate fertility, symptoms, function, access, and goals
Calculate carboplatin exposure
Carboplatin dose in milligrams is commonly target AUC multiplied by GFR plus 25. Use the protocol-specified renal estimate, confirm units and caps, and reassess when kidney function or body composition changes.
Attribute conventional toxicity
Paclitaxel commonly drives neuropathy, alopecia, marrow suppression, and hypersensitivity risk. Platinum compounds add marrow, renal, electrolyte, auditory, neurologic, and hypersensitivity concerns in drug-specific patterns.
Recognize vascular and immune emergencies
Bevacizumab can cause severe hypertension, proteinuria, hemorrhage, thrombosis, impaired wound healing, perforation, or fistula. Checkpoint inhibitors can inflame any organ, and early recognition plus graded management is essential.
Monitor targeted and ADC toxicity
PARP inhibitors require serial CBC and product-specific organ and cardiovascular review. Mirvetuximab and tisotumab require distinct ocular protocols. Avutometinib and defactinib add ocular, skin, muscle, liver, cardiac, and interaction surveillance.
Integrate the human treatment plan
Antiemesis, pain, bowel and bladder care, thrombosis, nutrition, neuropathy, fertility, menopause, sexual health, mood, financial access, survivorship, palliative care, and clinical trials belong in the same plan as antitumor therapy.
Quick check
Lesson
Preserve Fertility, Function, and Goals
Cancer care continues beyond a regimen. Fertility, ovarian function, sexual health, symptom relief, rehabilitation, recurrence surveillance, practical access, and evolving goals belong in the treatment architecture from diagnosis onward.
- Fertility preservation
- Treatment-induced menopause
- Sexual health
- Palliative care
- Survivorship
- Clinical trials and access
Address reproductive goals and treatment effects before therapy
Integrate palliative expertise with active anticancer treatment
Monitor recurrence, late effects, sexual health, and preventive care
Use shared decisions, trials, and practical support as disease changes
Plan before treatment changes fertility
Discuss fertility goals before surgery, pelvic radiation, or gonadotoxic systemic therapy whenever time and disease allow. Coordinate reproductive endocrinology, genetic counseling, and gynecologic oncology without delaying urgent care.
Treat menopause and sexual health directly
Surgical or treatment-induced menopause can affect vasomotor symptoms, bone, cardiovascular risk, sleep, mood, vaginal health, and sexual function. Management must account for cancer histology, hormone sensitivity, thrombosis risk, and patient priorities.
Integrate palliative care early
Palliative care can improve pain, nausea, bowel and bladder symptoms, fatigue, sleep, mood, communication, and caregiver support while disease-directed treatment continues. It is not restricted to the final days of life.
Build survivorship around actual exposure
Follow-up combines recurrence assessment with late-effect monitoring, preventive care, rehabilitation, bone and cardiovascular health, hereditary implications, and a clear route back to oncology for new symptoms.
Revisit goals, trials, and access
At every transition, reassess what matters to the patient, what treatment can realistically accomplish, clinical-trial eligibility, transportation, financial toxicity, caregiving, and advance care planning.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 136 question bank.
Each attempt draws a fresh set and rearranges the answer choices.